Chain in Crohn's Disease 2 b Up-Regulation of the IL-12 Receptor

Crohn’ s disease (CD) is a chronic intestinal inflammatory disorder characterized by aberrant mucosal Th1 cell activation and production of IL-12, the major Th1-driving factor. The T cell response to IL-12 is dependent on the expression of a specific receptor composed of two subunits, termed IL-12R b 1 and IL-12R b 2. The content of IL-12R b 2, as measured at the mRNA level, is crucial in regulating Th1 differentiation. In this study we therefore investigated IL-12R b 2 RNA transcripts in CD . IL-12R b 2 expression was increased in active CD as well as Helicobacter pylori (HP)-associated gastritis and Salmonella colitis compared with that in inactive CD, ulcerative colitis, noninflammatory controls, and celiac disease. In contrast, IL-12R b 1 transcripts were expressed at comparable levels in all samples. In CD, IL-12R b 2 expression strictly correlated with tyrosine phosphorylation of STAT4, a key component of the IL-12-dependent Th1 polarization. This was associated with a pronounced expression of IFN- g . Transcripts for IL-12/p40 were detected in CD, HP-positive, and Salmonella colitis patients, but not in celiac disease, indicating that IL-12R b 2 up-regulation occurs only in IL-12-associated Th1 gastrointestinal diseases. Finally, we showed that stimulation of lamina propria mononuclear cells with IL-12 enhanced IL-12R b 2, suggesting that IL-12 regulates IL-12R b 2 expression in human gastrointestinal mucosa. The data show that the signaling pathway used by IL-12 to induce Th1 differentiation is increased at the site of disease in CD, further supporting the view that IL-12/IL-12R signals contribute to the inflammatory PBMC were obtained from three CD and three UC patients, and three non-IBD controls. Biopsy specimens from the distal duodenum of four patients with untreated celiac disease and four normal controls were obtained during upper gastrointestinal endoscopy. Diagnosis of celiac dis- ease was made according to the original or revised European Society for Pediatric Gastroenterology and Nutrition criteria for celiac disease (24, 25). The histopathologic diagnosis was based on typical mucosal lesions with crypt cell hyperplasia, villous atrophy, and increased number of intraepi- thelial lymphocytes. All celiac disease patients were positive for anti-endomysial and anti-gliadin Abs. Control patients were under investigation for gastrointestinal symptoms, but had normal histology and were anti-endomysial and anti-gliadin Ab negative. Additional samples were taken from the gastric antrum of three patients with documented diagnosis of Helicobacter pylori (HP)-associated gastritis and three normal controls (HP-negative subjects). Biopsy specimens were snap-frozen in liquid ni-trogen and stored at 2 80°C until used. The study was approved by the department ethical committee.

[1]  N. Glaichenhaus,et al.  The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Leonard,et al.  Autocrine regulation of IL-12 receptor expression is independent of secondary IFN-gamma secretion and not restricted to T and NK cells. , 1999, Journal of immunology.

[3]  T. Macdonald,et al.  T cells orchestrate intestinal mucosal shape and integrity. , 1999, Immunology today.

[4]  L. Showe,et al.  Depressed IL-12-mediated signal transduction in T cells from patients with Sézary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4. , 1999, Journal of immunology.

[5]  C. Surowy,et al.  Direct interaction of STAT4 with the IL-12 receptor. , 1999, Archives of biochemistry and biophysics.

[6]  L. Fabbri,et al.  Antibodies to the IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo. , 1999, Journal of immunology.

[7]  John T. Chang,et al.  Regulation of Interleukin (IL)-12 Receptor β2 Subunit Expression by Endogenous IL-12: A Critical Step in the Differentiation of Pathogenic Autoreactive T Cells , 1999, The Journal of experimental medicine.

[8]  P. Barnes,et al.  Expression of the IL-12 Receptor β1 and β2 Subunits in Human Tuberculosis , 1999, The Journal of Immunology.

[9]  F. Pallone,et al.  Interleukin 12 and Th1 responses in inflammatory bowel disease , 1998, Gut.

[10]  F. Pallone,et al.  Response of human intestinal lamina propria T lymphocytes to interleukin 12: additive effects of interleukin 15 and 7 , 1998, Gut.

[11]  K. Lundin,et al.  Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease. , 1998, Gastroenterology.

[12]  C. Fiocchi Inflammatory bowel disease: etiology and pathogenesis. , 1998, Gastroenterology.

[13]  J. Casanova,et al.  Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. , 1998, Science.

[14]  J. Cézard,et al.  Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease. , 1998, The American journal of pathology.

[15]  M. Pla,et al.  Th1 response in Salmonella typhimurium-infected mice with a high or low rate of bacterial clearance , 1997, Infection and immunity.

[16]  G. Morrone,et al.  Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. , 1997, Gastroenterology.

[17]  M. Biffi,et al.  Selective Expression of an Interleukin-12 Receptor Component by Human T Helper 1 Cells , 1997, The Journal of experimental medicine.

[18]  S. Szabo,et al.  Regulation of the Interleukin (IL)-12R β2 Subunit Expression in Developing T Helper 1 (Th1) and Th2 Cells , 1997, The Journal of experimental medicine.

[19]  F. Annunziato,et al.  Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. , 1997, The American journal of pathology.

[20]  H. Yang,et al.  A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[21]  K. Tesselaar,et al.  Lack of IL-12 signaling in human allergen-specific Th2 cells. , 1996, Journal of immunology.

[22]  M. Neurath,et al.  Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. , 1996, Journal of immunology.

[23]  J. Ihle STATs: Signal Transducers and Activators of Transcription , 1996, Cell.

[24]  K. Ewe,et al.  Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) , 1995, Clinical and experimental immunology.

[25]  M. Neurath,et al.  Antibodies to interleukin 12 abrogate established experimental colitis in mice , 1995, The Journal of experimental medicine.

[26]  E. Petricoin,et al.  Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  L. Biancone,et al.  Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis. , 1995, Gastroenterology.

[28]  G. Trinchieri,et al.  Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. , 1994, Blood.

[29]  S. Guandalini,et al.  Revised criteria for diagnosis of coeliac disease , 1990 .

[30]  C. Smith,et al.  Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. , 1986, Gut.

[31]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[32]  S. Truelove,et al.  Cortisone in ulcerative colitis; final report on a therapeutic trial. , 1955, British medical journal.